 San Diego, Calif, April 15, 2021 GLOBE NEWSWIRE -- Skye Bioscience, Inc. OTCQB: SKYE SKYE or the Company, a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, announced today that Punit Dhillon, CEO, Skye Bioscience will present a virtual corporate overview at the Sequire Cannabis Investor Conference and Planet Microcap Showcase next week. Details are as follows: 